MedTrace Logo

Linezolid for Treatment of Nontuberculous Mycobacterial Diseases

NCT03220074 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-11-20

No results posted yet for this study

Summary

A prospective open study to determine the efficacy and tolerability of oral linezolid 600mg./day for the treatment of 40 patients with nontuberculous mycobacterial diseases will be conducted at Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Conditions

  • Non-tuberculous Mycobacterial Infections

Interventions

DRUG

Oral Tablet

study drug given and monitored for efficacy and tolerability

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

  • Siam Pharmaceutical Ltd.

    collaborator UNKNOWN

Principal Investigators

  • Yupin Suputtamongkol, MD · Mahidol University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2021-06-15
Completion
2022-06-15

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03220074 on ClinicalTrials.gov